Hotez is credibly describing his actual work developing affordable vaccines — the $2-3 per dose figure and non-profit approach are documented. The '100 million people' reach claim is harder to independently verify without current deployment data. His frustration at critics fixating on an old joke rather than his public health contributions is valid commentary, though characterizing opponents as 'lightweights' is rhetorical pushback rather than factual assertion. The research search results appear to mix legitimate vaccine science (blood clotting mechanisms) with fringe sources attacking vaccines broadly — the mixed bag suggests his complaint about bad-faith criticism has some basis.